🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesHas anyone dealt with glp-1 and peripheral arterial disease? Page 5

Has anyone dealt with glp-1 and peripheral arterial disease?

traveltech_sara Fri, Jan 31, 2025 at 6:48 PM 24 replies 2,011 viewsPage 5 of 5
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Feb 8, 2025 at 5:39 AM#21
Dr.GutHealth said:
Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off losartan entirely!

CRP reduction on cardiovascular risk — this is the lab result that excites me most:

Baseline hsCRP: 5.0 mg/L (high cardiovascular risk)
Month 6 hsCRP: 1.5 mg/L (moderate risk)
Month 12 hsCRP: 0.3 mg/L (low risk)

This level of inflammatory marker reduction is comparable to what you'd see with statin therapy. Combined with the weight loss, my 10-year ASCVD risk score dropped from 12% to 4%. My cardiologist is genuinely impressed.

21 19amsterdam_pete, LondonLisa, mike_nyc and 18 others
Reply Quote Save Share Report
AmyNC_wife
Member
634
2,890
Jun 2024
North Carolina
Feb 10, 2025 at 3:57 PM#22

One thing that is still open after Dr.GutHealth’s answer:

What did you change at the same time, and can you separate the two now?

22 20julia.endo, JessicaM_2024, TomFromTexas and 19 others
Reply Quote Save Share Report
HPLC_Greg
Senior Member
1,890
8,901
Feb 2024
Research Triangle, NC
Feb 13, 2025 at 2:17 AM#23
PharmacoVig_BOS said:
CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 5.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

I'm 55 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

13 months later: down 40 lbs, off atorvastatin, A1C from 8.0% to 5.5%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

Last edited: Feb 13, 2025 at 8:17 AM
23 21RetaRick_CA, JenPlateau, SallyK_inj and 20 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Feb 15, 2025 at 12:38 PM#24
PharmacoVig_BOS said:
CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 5.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…
PharmacoVig_BOS said:
...we don't know the long-term effects of cardiovascular risk...

This is a fair point, and I think intellectual honesty requires acknowledging it. GLP-1 agonists in their current form have ~8-10 years of human exposure data. That's not nothing, but it's not 30+ years either.

However: the risk-benefit calculation should also consider the KNOWN long-term effects of untreated obesity — diabetes, cardiovascular disease, cancer, joint destruction, reduced lifespan by 5-10 years.

Uncertainty about GLP-1 long-term safety vs certainty about obesity consequences. The calculus seems clear to me, but reasonable people can disagree.

Last edited: Feb 15, 2025 at 6:38 PM
24 22kim_atl_prep, sarah_TO, wendy_avl and 21 others
Reply Quote Save Share Report
Dr.EM_Chicago
Member
567
2,567
May 2024
Chicago, IL
Feb 17, 2025 at 11:01 PM#25
PharmacoVig_BOS said:
CRP reduction on cardiovascular risk — this is the lab result that excites me most: Baseline hsCRP: 5.0 mg/L (high cardiovascular risk) Month 6 hsCRP:…

Bookmarking. The distinction being drawn above is the one nobody else makes.

Last edited: Feb 18, 2025 at 3:01 AM
25 23lisa_labSD, adam_van, Dr.SurgeonPGH and 22 others
Reply Quote Save Share Report
1345

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register